A Drug Utilization Study of Radium-223 in Sweden

Bayer

Status: Completed

Conditions: Neoplasms

Treatments: Other: Radium-223 dichloride (Xofigo, BAY88-8223)

Study type: Observational

Funder types: Industry

Identifiers

NCT02331303

17399

Details and patient eligibility

About

The objective of this study is to evaluate the extent of potential off-label use of Xofigo in Sweden.

Enrollment: 37 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients receiving Xofigo with data recorded at nuclear medicine centers in Sweden between 01 July 2014 and 30 June 2016 will be included in the study

Exclusion criteria

• Patients receiving Xofigo in a clinical trial will not be included in this study

Trial design

37 participants in 1 patient group

Group1

Description:

This is a single-arm descriptive observational drug utilization study based on secondary data collection of patients treated with Xofigo in Sweden. This study will include patients receiving treatment of Xofigo at certified nuclear medicine centers across Sweden during a two year period.

Treatment:

Other: Radium-223 dichloride (Xofigo, BAY88-8223)